蓝帆医疗：公司心脑血管事业部营业收入国外占比约60%

Core Insights - The company, Bluestar Medical, reported that its cardiovascular division generates approximately 60% of its revenue from international markets and 40% from domestic markets, with expectations for an increase in domestic revenue share in the future [1] - In the first half of 2025, the company's cardiovascular division is projected to achieve nearly 700 million yuan in revenue, with around 650 million yuan coming from coronary business and 50 million yuan from heart valve business [1]